← Leaderboards
Anjan Debnath
University Of California, San Diego
$2,418,635
Attributed
$3,032,466
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $488.3K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,032,466 · 7
By mechanism
R21$3,032,466 · 7
Top collaborators
- Carlo Ballatore4 shared
- Conor Caffrey4 shared
- Larissa M. Podust2 shared
Others in their field
Other Emerging Leaders on “Infection”
- Chanza Baytop · Westat, Inc.$271,217,917
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$207,651,224
- Kimberly Smith · Ppd Development Lp$115,671,664
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
Research focus
InfectionPharmaceutical PreparationsParasitesEfficacy StudyIn VivoDrug DiscoveryMouse ModelIn VitroBiologyNational Institute Of Allergy And Infectious DiseaseAmoeba GenusAnimal ModelLeadFutureRare DiseasesAcanthamoebaAntimicrobialDrug IndustryPharmacokinetics And PharmacodynamicsParasitologyPhenotypeBrainDoseNovel Therapeutics
Grant awards (14)
Sterol Biosynthesis Inhibitors as Drug Leads for the Treatment of Acanthamoeba Eye Infection$197,500
R21 · FY2025 · EY · contact PI
Development of brain-penetrant drugs targeting N. fowleri primary amoebic meningoencephalitis (PAM)$194,497
R21 · FY2025 · AI · contact PI
Development of brain-penetrant drugs targeting N. fowleri primary amoebic meningoencephalitis (PAM)$239,563
R21 · FY2024 · AI · contact PI
Sterol Biosynthesis Inhibitors as Drug Leads for the Treatment of Acanthamoeba Eye Infection$237,000
R21 · FY2024 · EY · contact PI
A machine learning-based screen of marine natural products to identify new leads for the treatment of Acanthamoeba eye infection$197,500
R21 · FY2023 · EY · contact PI
A machine learning-based screen of marine natural products to identify new leads for the treatment of Acanthamoeba eye infection$237,000
R21 · FY2022 · EY · contact PI
Latrunculin B as a new drug lead for the treatment of Acanthamoeba keratitis$191,575
R21 · FY2022 · EY · contact PI
Latrunculin B as a new drug lead for the treatment of Acanthamoeba keratitis$236,875
R21 · FY2021 · EY · contact PI
HMG-CoA Reductase Inhibitors as New Drug Leads for Naegleria Infection$197,240
R21 · FY2021 · AI · contact PI
Brain Penetrant Microtubule-Stabilizers to Treat CNS-invasive Parasitic Diseases$252,094
R21 · FY2020 · AI
HMG-CoA Reductase Inhibitors as New Drug Leads for Naegleria Infection$236,250
R21 · FY2020 · AI · contact PI
Brain Penetrant Microtubule-Stabilizers to treat CNS-invasive parasitic diseases$193,750
R21 · FY2019 · AI
Brain Penetrant Microtubule-Stabilizers to Treat CNS-invasive Parasitic Diseases$189,122
R21 · FY2019 · AI
Brain Penetrant Microtubule-Stabilizers to treat CNS-invasive parasitic diseases$232,500
R21 · FY2018 · AI